Medicina personalizzata nel pre-diabete e nel diabete di tipo 2 precoce (PREDICT)
Personalised Medicine in Prediabetes - Towards Preventing Diabetes in Individuals at Risk
Prediabetes is a common condition in overweight individuals affecting approximately 35% of American adults and 30% of Australian adults. Like diabetes, prediabetes is a serious risk factor for cardiovascular disease, eye, kidney and liver disease, and some types of cancer.
Appropriate blood glucose control is crucial in preventing pre-diabetes complications and onset of diabetes, yet clinical practice, backed by randomised trials, reports that many patients treated with standard dietary guidelines or with the first-line treatment of diabetes patients, metformin, do not improve blood glucose control sufficiently.
The overarching goal of the present project is to improve the efficacy of metformin mono-therapy in pre-diabetes and early type 2 diabetes.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Prediabetes is common in overweight and obese individuals and, as with frank diabetes, it is a risk factor for cardiovascular disease, cognitive dysfunction, fatty liver, kidney, ophthalmic, renal and neuropathic disease, and cancer.
Effective management of dysglycemia in pre-diabetes and diabetes and prevention of diabetes in individuals at risk reduce the risk of organ damage and associated co-morbidities and improves the affected individuals' quality of life.
Metformin, an oral biguanide, is the first-line treatment of newly-diagnosed type 2 diabetes patients, and the pharmacological choice for preventing diabetes in individuals with pre-diabetes. Metformin is an ideal medication to initiate for diabetes prevention, due to its excellent safety profile (lack of hypoglycemia), neutral to marginally beneficial effect on body weight, evidence of cardio-protection, and low cost. However, clinical practice, backed by randomised clinical trials, suggests that metformin mono-therapy fails to achieve glycemic goals in 20-40% of type 2 diabetes patients and to prevent diabetes in approximately 20% of individuals with pre-diabetes.
While the mode of action of metformin is still being investigated, the liver and the gastrointestinal tract are thought to be the main targets responsible for the improvement in glycemia. An increasing body of evidence suggests that the gut microbiota play an important role in obesity, prediabetes and diabetes, and alterations in gut microbial composition have been described in individuals with type 2 diabetes and pre-diabetes. Interestingly, metformin-treated diabetes patients have a "healthier" gut microbial composition compared with treatment-naïve diabetes patients, and changes in gut microbial composition with metformin treatment has been suggested to contribute to the therapeutic effect of the medication.
Randomised, clinical study with parallel assignment and single-masking will be performed in treatment-naïve individuals with pre-diabetes or early type 2 diabetes (diagnosed in the last 6 months) aiming to compare the effect of metformin (extended release [XR]) 1500 mg/d administered with personalized diet (based on the Weizmann Institute Personalized Nutrition Project) or administered with a healthy (low fat) diet.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2010
- Garvan Institute of Medical Research
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion criteria:
- Prediabetes or early-stage type 2 diabetes according to the American Diabetes Association (2019) diagnostic criteria, with HbA1c ≤8.0% (64 mmol/mol).
- Women of childbearing potential willing to take precautions to avoid pregnancy throughout the study and for 3 months after the end of treatment.
- Willingness to provide written informed consent and willingness to participate and comply with the study.
Exclusion Criteria:
- Females planning a pregnancy during the course of the research or 3 months after completion of the research project. Females who breastfeed.
- Patients with type 1 diabetes, chronically active inflammatory disease, neoplastic disease in the previous 3 years, chronic gastrointestinal disorders, including inflammatory bowel disease or celiac.
- Liver enzymes ALT and/or AST>3-times normal range limit.
- Abnormal renal function as measured by (eGFR<45 mL/min/1.73m^2).
- Individuals with a history of a psychological illness or condition that may interfere with the individual's ability to understand the requirements of the study.
- Normo-glycaemia.
- HbA1c>8.0%
- Cardiovascular event in the previous 6 months.
- Current or recent (within 24 months) treatment with a glucose lowering medication (i.e. GLP-1 receptor agonist, SGLT2 inhibitor, thiazolidinedione, sulfonylurea, DPP-4 inhibitor or insulin).
- Current or recent (within 3 months) treatment with metformin.
- Treatment with an oral steroid.
- Treatment with antibiotics in the last 3 months.
- Treatment with immunosuppressive medications.
- Treatment with medications known to interact with metformin, including cimetidine, vitamin K antagonists and nifedipine.
- Substance abuse.
- Participants who had received an investigational new drug within the last 6 months.
- Participants involved in another clinical study.
- Participants who actively lose weight.
- Participants who had a bariatric surgery.
- Any reason the Investigator believes the participant is not likely to be adherent to the study treatment and protocol, including non-adherence to run-in.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Comparatore placebo: Metformin + Healthy diet
Metformin (1500 mg/d, Extended Release) + Healthy, low fat diet |
Metformin (1500 mg/d, Extended Release) + Healthy, low fat diet
Altri nomi:
|
|
Comparatore attivo: Metformin + Personalized diet
Metformin (1500 mg/d, Extended Release) + Personalized diet based on an algorithm developed at the Weizmann Institute of Science (Zeevi et al, Cell 2015) |
Metformin (1500 mg/d, Extended Release) + Algorithm-based personalized diet |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Mean change in glycated haemoglobin (HbA1C, %) from baseline
Lasso di tempo: 6 months
|
Difference in the reduction of HbA1C between the groups |
6 months
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Total daily time of interstitial glucose levels below 7.8 mmol/L (140 mg/dL)
Lasso di tempo: 6 months
|
Difference in the time (minutes) per day with interstitial glucose measured below 7.8 mmol/L (140 mg/dL) between the groups |
6 months
|
|
Glycaemic variability
Lasso di tempo: 6 months
|
Difference in the glycaemic variability as derived from CGM between the groups |
6 months
|
|
Body weight
Lasso di tempo: 6 months
|
Difference in the magnitude of weight loss between the groups |
6 months
|
|
Body fat mass
Lasso di tempo: 6 months
|
Difference in body fat mass composition as assessed using dual-energy X-ray absorptiometry (DXA) between the groups |
6 months
|
|
Abdominal visceral fat volume
Lasso di tempo: 6 months
|
Difference in the abdominal visceral fat volume as assessed using DXA between the groups |
6 months
|
|
Serum low-density lipoprotein (LDL)-cholesterol concentration
Lasso di tempo: 6 months
|
Difference in serum LDL-cholesterol between the groups |
6 months
|
|
Serum high-density lipoprotein (HDL)-cholesterol concentration
Lasso di tempo: 6 months
|
Difference in serum HDL-cholesterol concentration between the groups |
6 months
|
|
Serum triglycerides concentration
Lasso di tempo: 6 months
|
Difference in serum triglycerides between the groups |
6 months
|
|
Blood pressure
Lasso di tempo: 6 months
|
Difference in diastolic and systolic blood pressure between the groups |
6 months
|
|
Liver fat
Lasso di tempo: 6 months
|
Difference in liver fat measured by the Fibroscan's controlled attenuation parameter (CAP) function between the groups |
6 months
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Gut microbiome (exploratory)
Lasso di tempo: 6 months
|
Difference in gut microbiome features between the groups |
6 months
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Dorit Samocha-Bonet, PhD, Garvan Institute of Medical Research
- Investigatore principale: Jerry Greenfield, MD, PhD, Garvan Institute of Medical Research
- Investigatore principale: Eran Elinav, MD, PhD, Weizmann Institute of Science
- Investigatore principale: Eran Segal, PhD, Weizmann Institute of Science
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema endocrino
- Malattie metaboliche
- Disturbi del metabolismo del glucosio
- Diabete mellito
- Iperinsulinismo
- Iperglicemia
- Malattie nutrizionali e metaboliche
- Diabete mellito, tipo 2
- Resistenza all'insulina
- Intolleranza al glucosio
- Prodotti chimici organici
- Terapie
- Dieta, cibo e nutrizione
- Fenomeni fisiologici
- Fenomeni fisiologici nutrizionali
- Terapia dietetica
- Terapia nutrizionale
- Biguanides
- Guanidine
- Amidine
- Metformina
- Dieta
- Dieta, sano
- Dieta, restritti a grasso
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- SVH 17/080
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .